Compare AMST & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMST | IMNN |
|---|---|---|
| Founded | 2017 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 12.5M |
| IPO Year | 2020 | 1985 |
| Metric | AMST | IMNN |
|---|---|---|
| Price | $2.11 | $3.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | ★ 508.1K | 79.8K |
| Earning Date | 02-09-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $193,505.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 68.56 | N/A |
| 52 Week Low | $1.79 | $2.99 |
| 52 Week High | $4.78 | $41.22 |
| Indicator | AMST | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 42.77 |
| Support Level | $1.87 | $3.38 |
| Resistance Level | $2.15 | $3.88 |
| Average True Range (ATR) | 0.13 | 0.33 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 72.22 | 43.81 |
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).